LIVAGEN is a Khavinson bioregulator tetrapeptide that users primarily take to improve insomnia and overall sleep quality. The community‑driven regimen centers on a daily 200 µg subcutaneous dose, with timing and cycling left to individual preference. The only clear trade‑off is that it has no FDA‑approved indication, so all human use is off‑label and compounded. Users have occasionally reported altered sleep patterns and vivid dreams, while injection‑site reactions, flushing, edema, nausea and other typical peptide side effects have not emerged as consistent issues.
Data last updated
Measured on 4 of 6 axes
Evidence shape
The only published data for Livagen come from animal‑only, preclinical mechanistic studies, so human evidence is absent. That single indication is the sole focus of the existing research, and no blinded or completed trials have been reported. The lack of any registered or finished human studies means there is currently no clinical evidence to support its use.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 1 out-of-stock offer not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How LIVAGEN is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
A single anecdotal report listed a dose of 200 mcg administered subcutaneously, with no frequency or cycling information provided, according to the source.